Previous close | 233.56 |
Open | 231.74 |
Bid | 232.84 x 900 |
Ask | 233.25 x 900 |
Day's range | 229.45 - 237.11 |
52-week range | 208.35 - 526.00 |
Volume | |
Avg. volume | 942,435 |
Market cap | 36.352B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | 38.07 |
EPS (TTM) | 6.11 |
Earnings date | 25 Apr 2022 - 29 Apr 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 436.19 |
With its stock down 31% over the past month, it is easy to disregard Illumina (NASDAQ:ILMN). We, however decided to...
A Delaware jury on Friday ordered Illumina Inc to pay more than $333 million to a U.S. unit of Chinese genomics company BGI Group after finding that Illumina's DNA-sequencing systems infringed two patents. The jury also said Illumina infringed the patents willfully, and that three patents it had accused BGI's Complete Genomics unit of infringing were invalid.
Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.